Log In
Print this Print this

Elelyso, Uplyso, alfataliglicerase, taliglucerase alfa (formerly prGCD)

  Manage Alerts
Collapse Summary General Information
Company Protalix BioTherapeutics Inc.
DescriptionPlant cell-expressed recombinant form of human glucocerebrosidase (GCase)
Molecular Target Glucocerebrosidase (GBA) (GCase)
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentMarketed
Standard IndicationGaucher's disease
Indication DetailsTreat Gaucher's disease; Treat Type I Gaucher's disease; Treat Type I Gaucher's disease in pediatric patients
Regulatory Designation U.S. - Expanded Access (Treat Gaucher's disease);
U.S. - Fast Track (Treat Gaucher's disease);
U.S. - Orphan Drug (Treat Gaucher's disease);
U.S. - Special Protocol Assessment (Treat Gaucher's disease);
EU - Orphan Drug (Treat Type I Gaucher's disease);
Australia - Orphan Drug (Treat Gaucher's disease);
Canada - Standard Review (Treat Gaucher's disease)
PartnerPfizer Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today